3320 — China Resources Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- HK$30.09bn
- HK$84.09bn
- CNY244.70bn
- 72
- 96
- 55
- 91
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.32 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -0.48% | ||
| Dividend Yield (f) | 3.59% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 1.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.11 | ||
| EV to EBITDA | 5.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.01% | ||
| Return on Equity | 8.61% | ||
| Operating Margin | 4.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 180,260.02 | 178,299.73 | 196,534.2 | 218,182.99 | 244,703.88 | 263,712.6 | 290,527.62 | 8.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -20.72 | +26.77 | -2.45 | +7.61 | +26.17 | -5.59 | +11.9 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
Directors
- Yuewei Han NEC (53)
- Xiaosong Bai CEO (50)
- Jingwen Weng CFO (45)
- Yi Feng CEX (59)
- Dengfeng Gao CEX (49)
- Huawei Qiu CEX (54)
- Jun Wu SVP (58)
- Huijun Yin SVP (50)
- Ran Tao VPR (55)
- Qingsheng Meng VPR (52)
- Jianjun Wu VPR (49)
- Song Jin OTH (45)
- Yaoming Liu OTH (59)
- Xiaoqing Lu OTH (52)
- Hong Mu OTH
- Na Tang OTH (44)
- Bingxiang Zhao OTH (48)
- Chi Lik Lo SEC (71)
- Bo Hou NED (57)
- Ruifang Jiao NED (44)
- Guolong Lin NED (55)
- Ying Tan NED (59)
- Tingmei Fu NID (55)
- Kin Fun Kwok NID (71)
- Mo Han Shing NID (65)
- Kejian Zhang NID (65)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 10th, 2007
- Public Since
- October 28th, 2016
- No. of Employees
- 72,986
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 6,282,510,461
- Address
- Room 4104-05, 41F,China Resources Buldng
- Web
- https://www.crpharm.com/
- Phone
- +852 null25938991
- Auditors
- Ernst & Young
Upcoming Events for 3320
Dividend For 3320.HK - 0.1697 HKD
Half Year 2024 China Resources Pharmaceutical Group Ltd Earnings Release
Similar to 3320
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the China Resources Pharmaceutical share price?
As of Today at 19:05 UTC, shares in China Resources Pharmaceutical are trading at HK$4.79. This share price information is delayed by 15 minutes.
How has the China Resources Pharmaceutical share price performed this year?
Shares in China Resources Pharmaceutical last closed at HK$4.79 and the price had moved by -29.35% over the past 365 days. In terms of relative price strength the China Resources Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -26.26% over the past year.
What are the analyst and broker recommendations for China Resources Pharmaceutical?
The overall consensus recommendation for China Resources Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the China Resources Pharmaceutical dividend yield?
The China Resources Pharmaceutical dividend yield is 3.48% based on the trailing twelve month period.
Does China Resources Pharmaceutical pay a dividend?
Last year, China Resources Pharmaceutical paid a total dividend of CNY0.15, and it currently has a trailing dividend yield of 3.48%.Looking ahead, shares in China Resources Pharmaceutical are due to go ex-dividend on 2024-06-04 and the next dividend pay date is 2024-07-19.
When does China Resources Pharmaceutical next pay dividends?
China Resources Pharmaceutical are due to go ex-dividend on 2024-06-04 and the next dividend pay date is 2024-07-19. The historic dividend yield on China Resources Pharmaceutical shares is currently 3.48%.
How do I buy China Resources Pharmaceutical shares?
To buy shares in China Resources Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of China Resources Pharmaceutical?
As of the previous close price of HK$4.79, shares in China Resources Pharmaceutical had a market capitalisation of HK$30.09bn.
Where are China Resources Pharmaceutical shares listed?
Here are the trading details for China Resources Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3320
What kind of share is China Resources Pharmaceutical?
Based on an overall assessment of its quality, value and momentum China Resources Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a China Resources Pharmaceutical share price forecast for 2024?
The analyst consensus target price for shares in China Resources Pharmaceutical is HK$7.60. That is 58.75% above the last closing price of HK$4.79.
Analysts covering China Resources Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of CNY0.68 for the next financial year.
What is the trend in the China Resources Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like China Resources Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -4.94%.
As of the last closing price of HK$4.79, shares in China Resources Pharmaceutical were trading -8.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the China Resources Pharmaceutical PE Ratio?
The China Resources Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 6.32. The shares last closed at HK$4.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of China Resources Pharmaceutical?
China Resources Pharmaceutical's management team is headed by:
- Yuewei Han - NEC
- Xiaosong Bai - CEO
- Jingwen Weng - CFO
- Yi Feng - CEX
- Dengfeng Gao - CEX
- Huawei Qiu - CEX
- Jun Wu - SVP
- Huijun Yin - SVP
- Ran Tao - VPR
- Qingsheng Meng - VPR
- Jianjun Wu - VPR
- Song Jin - OTH
- Yaoming Liu - OTH
- Xiaoqing Lu - OTH
- Hong Mu - OTH
- Na Tang - OTH
- Bingxiang Zhao - OTH
- Chi Lik Lo - SEC
- Bo Hou - NED
- Ruifang Jiao - NED
- Guolong Lin - NED
- Ying Tan - NED
- Tingmei Fu - NID
- Kin Fun Kwok - NID
- Mo Han Shing - NID
- Kejian Zhang - NID